Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

HCV NS5A replication complex inhibitors.

Gao M, O'Boyle DR 2nd, Roberts S.

Curr Opin Pharmacol. 2016 Oct;30:151-157. doi: 10.1016/j.coph.2016.07.014. Review.

PMID:
27643675
2.

Synergistic Activity of Combined NS5A Inhibitors.

O'Boyle DR 2nd, Nower PT, Gao M, Fridell R, Wang C, Hewawasam P, Lopez O, Tu Y, Meanwell NA, Belema M, Roberts SB, Cockett M, Sun JH.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.

3.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.

Sun JH, O'Boyle DR 2nd, Fridell RA, Langley DR, Wang C, Roberts SB, Nower P, Johnson BM, Moulin F, Nophsker MJ, Wang YK, Liu M, Rigat K, Tu Y, Hewawasam P, Kadow J, Meanwell NA, Cockett M, Lemm JA, Kramer M, Belema M, Gao M.

Nature. 2015 Nov 12;527(7577):245-8. doi: 10.1038/nature15711. Epub 2015 Nov 4.

PMID:
26536115
4.

Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Wang C, Jia L, O'Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14. Epub 2014 Jun 16.

5.

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA.

J Med Chem. 2014 Mar 13;57(5):1643-72. doi: 10.1021/jm401793m. Epub 2014 Feb 3.

PMID:
24621191
6.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG.

J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12.

PMID:
24521299
7.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR 2nd, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1995-2012. doi: 10.1021/jm4016203. Epub 2014 Jan 17.

PMID:
24437689
8.

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

Belema M, Nguyen VN, St Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O'Boyle DR 2nd, Sun JH, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4428-35. doi: 10.1016/j.bmcl.2013.05.040. Epub 2013 May 23.

PMID:
23803586
9.

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.

O'Boyle DR 2nd, Nower PT, Sun JH, Fridell R, Wang C, Valera L, Gao M.

J Virol Methods. 2013 Oct;193(1):68-76. doi: 10.1016/j.jviromet.2013.04.024. Epub 2013 May 14.

PMID:
23684844
10.

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.

St Laurent DR, Serrano-Wu MH, Belema M, Ding M, Fang H, Gao M, Goodrich JT, Krause RG, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle DR 2nd, Pearce BC, Romine JL, Valera L, Sun JH, Wang YK, Yang F, Yang X, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1976-94. doi: 10.1021/jm301796k. Epub 2013 Apr 10.

PMID:
23573957
11.

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Roberts S, Fridell RA, Gao M.

Antimicrob Agents Chemother. 2013 May;57(5):2054-65. doi: 10.1128/AAC.02494-12. Epub 2013 Feb 12.

12.

HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

Lopez OD, Nguyen VN, St Laurent DR, Belema M, Serrano-Wu MH, Goodrich JT, Yang F, Qiu Y, Ripka AS, Nower PT, Valera L, Liu M, O'Boyle DR 2nd, Sun JH, Fridell RA, Lemm JA, Gao M, Good AC, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):779-84. doi: 10.1016/j.bmcl.2012.11.086. Epub 2012 Dec 3.

PMID:
23273521
13.

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.

Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, Jia L, Qiu D, Huang X, Altaf A, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11. Epub 2012 Jan 3.

14.

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR 2nd, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.

15.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M.

Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.

PMID:
21809362
16.

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

Qiu D, Lemm JA, O'Boyle DR 2nd, Sun JH, Nower PT, Nguyen V, Hamann LG, Snyder LB, Deon DH, Ruediger E, Meanwell NA, Belema M, Gao M, Fridell RA.

J Gen Virol. 2011 Nov;92(Pt 11):2502-11. doi: 10.1099/vir.0.034801-0. Epub 2011 Jul 27.

PMID:
21795470
17.

Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.

Lemm JA, Leet JE, O'Boyle DR 2nd, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M.

Antimicrob Agents Chemother. 2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11. Epub 2011 May 16.

18.

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

Romine JL, St Laurent DR, Leet JE, Martin SW, Serrano-Wu MH, Yang F, Gao M, O'Boyle DR 2nd, Lemm JA, Sun JH, Nower PT, Huang XS, Deshpande MS, Meanwell NA, Snyder LB.

ACS Med Chem Lett. 2011 Jan 11;2(3):224-9. doi: 10.1021/ml1002647. eCollection 2011 Mar 10.

19.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
20.

Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

O'Boyle DR 2nd, Nower PT, Lemm JA, Valera L, Sun JH, Rigat K, Colonno R, Gao M.

Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53.

21.

Specific inhibition of bovine viral diarrhea virus replicase.

Sun JH, Lemm JA, O'Boyle DR 2nd, Racela J, Colonno R, Gao M.

J Virol. 2003 Jun;77(12):6753-60.

22.

Functional conservations of the alkaline nuclease of herpes simplex type 1 and human cytomegalovirus.

Gao M, Robertson BJ, McCann PJ, O'Boyle DR, Weller SK, Newcomb WW, Brown JC, Weinheimer SP.

Virology. 1998 Sep 30;249(2):460-70.

23.

Identification of a novel peptide substrate of HSV-1 protease using substrate phage display.

O'Boyle DR 2nd, Pokornowski KA, McCann PJ 3rd, Weinheimer SP.

Virology. 1997 Sep 29;236(2):338-47.

24.

Stimulation of the herpes simplex virus type I protease by antichaeotrophic salts.

Yamanaka G, DiIanni CL, O'Boyle DR 2nd, Stevens J, Weinheimer SP, Deckman IC, Matusick-Kumar L, Colonno RJ.

J Biol Chem. 1995 Dec 15;270(50):30168-72.

25.

The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain.

O'Boyle DR 2nd, Wager-Smith K, Stevens JT 3rd, Weinheimer SP.

J Biol Chem. 1995 Mar 3;270(9):4753-8.

26.

Identification of the serine residue at the active site of the herpes simplex virus type 1 protease.

DiIanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonno RJ.

J Biol Chem. 1994 Apr 29;269(17):12672-6.

27.
28.

Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles.

Weinheimer SP, McCann PJ 3rd, O'Boyle DR 2nd, Stevens JT, Boyd BA, Drier DA, Yamanaka GA, DiIanni CL, Deckman IC, Cordingley MG.

J Virol. 1993 Oct;67(10):5813-22.

29.

Deletion of the VP16 open reading frame of herpes simplex virus type 1.

Weinheimer SP, Boyd BA, Durham SK, Resnick JL, O'Boyle DR 2nd.

J Virol. 1992 Jan;66(1):258-69.

30.

Latent herpes simplex virus type 1 transcription in human trigeminal ganglia.

Steiner I, Spivack JG, O'Boyle DR 2nd, Lavi E, Fraser NW.

J Virol. 1988 Sep;62(9):3493-6.

31.
33.

Restriction endonuclease patterns of cytomegalovirus after passage in humans.

Plotkin SA, Fraser NW, Parente M, O'Boyle DR 2nd.

J Infect Dis. 1987 Feb;155(2):317-9. No abstract available.

PMID:
3027194

Supplemental Content

Loading ...
Support Center